Aiosyn Mitosis: Mitotic figure counting
We provide an IVDR-certified application to aid clinical laboratories with the identification of mitotic figures in H&E sections.
The manual process is time-consuming and subject to variability, and there is a need for solutions to increase its efficiency and consistency of results. Aiosyn Mitosis Breast [1] uses deep learning to detect mitosis in whole slide images, saving pathologists time and providing laboratories with a more standard process for assessing tumor growth.
1. Aiosyn Mitosis Breast, for use in clinical diagnostics, has obtained CE-mark certification under the EU IVDR. In addition to Aiosyn Mitosis Breast, we offer Aiosyn Mitosis Research for biopharma and research institutions.
75% pathologists improved efficiency
75% pathologists improved efficiency
The algorithm helps laboratories improve the process of mitosis analysis. In a clinical performance study, 75% of participating pathologists were faster when supported by Aiosyn Mitosis Breast.
32.6% enhancement in consistency
32.6% enhancement in consistency
Aiosyn Mitosis Breast has been shown to reduce variability among observers, leading to a 32.6% improvement in consistency between pathologists.
AI integrated in your workflow
AI integrated in your workflow
Aiosyn Mitosis Research and Aiosyn Mitosis Breast are offered as a modular software solution that can be integrated into existing workflows, removing the need to adopt a different viewer.
Your workflow with Aiosyn Mitosis Breast
Our AI-powered solutions can be integrated with standard workflow providers. Slides are prepared as usual, and the algorithm analyzes images once uploaded to the platform.
Over 90% of surveyed pathologists who tried Aiosyn Mitosis Breast would like to use the algorithm in their daily practice.
“I am delighted that we finalized the clinical validation study for Aiosyn Mitosis Breast with Radboudumc. It was an immense project with 28 pathologists from 9 countries participating. Great to see how AI can benefit pathologists in a real clinical setting!”
Wouter Bulten, Chief Innovation Officer of Aiosyn
Improving mitosis counting for clinical diagnostics and biopharma
-
Aiosyn Mitosis Breast for clinical diagnostics
-
Aiosyn Mitosis Research for biopharma
-
Aiosyn Mitosis Breast assists pathologists in detecting mitotic figures in whole slide images of breast biopsies and resections. Mitoses are detected and highlighted by the algorithm before the pathologist opens the WSI, thereby indicating areas with mitotic activity and assisting in the quantification.
In a clinical performance study, 75% of participating pathologists were faster when supported by Aiosyn Mitosis Breast. On average, pathologists showed a 15.5% increase in productivity when reviewing resections. Additionally, the algorithm lead to a 32.6% improvement in consistency between pathologists
-
Aiosyn Mitosis Research aids research labs with the identification of mitotic figures in H&E sections. With improved and reproducible detection, new biomarkers can be discovered and researched more accurately.
Automated whole-slide level assessment enables the processing of caseloads that would not be possible with human annotators. By streamlining the process, Aiosyn Mitosis Research can assist laboratories in adopting a more consistent and efficient protocol for the identification of novel pathology-based biomarkers, resulting in improved and standardized results.
Aiosyn Mitosis news and articles
-
Aiosyn Mitosis Breast becomes the first AI-powered mitosis detection solution to achieve CE mark certification under IVDR
07 January, 2025 • By Anna Correas GrifollRead more -
Aiosyn’s AI-powered mitosis detection solution is now accessible in Sectra Amplifier Marketplace
02 May, 2024 • By Anna Correas GrifollRead more -
ZAS Netwerk partners with Aiosyn to evaluate AI-powered mitosis detection in clinical settings
25 March, 2024 • By Kama WitkowskaRead more
Questions? We are happy to answer
We will get back to you as soon as possible.
The most frequent questions about Aiosyn Mitosis Breast
Is the algorithm CE marked?
Yes. Aiosyn Mitosis Breast has obtained CE-mark certification under the EU IVDR.
What data and information are required to conduct a trial period?
You can request a demonstration of Aiosyn Mitosis Breast very easily. First, you upload a few whole-slide images to our secure online platform. Then, we apply the solution to detect mitotic figures throughout the image. Finally, we give you access to our online viewer where you can examine the product’s detections together with your images.
What are the IT requirements for integrating Aiosyn Mitosis Breast into our existing infrastructure?
We are a flexible provider of AI-powered solutions, and can accommodate most setups, with two common deployment options as follows. First, performing the integration via an existing marketplace, for example: Sectra Amplifier Marketplace, Paige AppLabTM, PathAI AISight, Proscia, etc. We work with most manufacturers to bring our products to your lab with ease. Second, integrating directly with your IMS or custom system via simple HTTP(S) API. In this case, we require that your system is able to send us notifications when a new image is available for processing, and later displaying the detections of the product (mitotic figures). Both deployment options are available on-premise (installed in your own hardware inside your network), or in the cloud (we use tier-1 infrastructure from AWS and Azure).
How does this solution differentiate itself from other AI solutions available on the market?
Aiosyn Mitosis Breast is the first AI-powered mitosis detection solution to achieve CE mark certification under IVDR. The application went through a rigorous validation and multi-center clinical performance study which demonstrated significant improvements in both efficiency and consistency among 28 pathologists across 9 countries when using it. Over 90% of surveyed pathologists who tried Aiosyn Mitosis Breast would like to use the algorithm in their daily practice. In addition, the solution is modular and can be integrated into existing workflows, minimizing investment and disruption of current processes.
What is the scaling capability for handling large cohorts of slides?
For large volumes, Aiosyn Mitosis Breast computing resources can be deployed in the cloud. This has the benefit of providing virtually unlimited scaling capabilities. When needed, extra hardware resources can be invoked to process a large number of slides in parallel, substantially reducing turnaround time. These resources are discarded after the workload is completed, limiting processing costs.
Is the algorithm compliant with GDPR and other data privacy regulations?
Yes, Aiosyn Mitosis Breast is compliant with GDPR and other standard regulations.
What are the available pricing models? Is there an option for per-slide pricing or is it subscription-based?
We establish the pricing models based on your needs and preferences. Both subscriptions and per-slide pricing are available.
